Treats complicated urinary tract infections (cUTI) including pyelonephritis caused by…. Sold as Vabomere. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Meropenem; Vaborbactam (sold as Vabomere), first approved Aug 29, 2017, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Vabomere | Part D | $2.4M | +111% | 138 |
| Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver TransplantationLiver Transplant, Carbapenem-resistant Enterobacterales · IRCCS Azienda Ospedaliero-Universitaria di Bologna | Phase 3 | Not yet recruiting | Aug 12, 2026 |
| Microbiological and Clinical Characteristics of Severe Infections Caused by Carbapenem-Resistant EnterobacteralesCarbapenem-Resistant Enterobacteriaceae Infection · Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — | Not yet recruiting | Sep 8, 2025 |
| Optimising TREATment for Severe Gram-Negative Bacterial InfectionsBloodstream Infection, Ventilator Associated Bacterial Pneumonia · National University of Singapore | Phase 4 | Recruiting | Jun 4, 2025 |
| A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract InfectionsGram Negative Infections · Menarini Group | Phase 2 | Recruiting | Feb 14, 2025 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute PyelonephritisAcute Pyelonephritis, Complicated Urinary Tract Infection · Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) | Phase 2 | Active, not recruiting | Nov 4, 2024 |
| Nosocomial Infections in ECMO PatientsAcute Respiratory Distress Syndrome, Nosocomial Infection · Policlinico Hospital | — | Active, not recruiting | Oct 4, 2022 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA